Skip to content

Dialectical Behavior Therapy for Adults With Autism Spectrum Disorders

Dialectical Behavior Therapy for Adults With Autism Spectrum Disorders Without Intellectual Disability: a Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04737707
Acronym
Autisemo
Enrollment
92
Registered
2021-02-04
Start date
2021-04-16
Completion date
2025-06-01
Last updated
2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorders

Brief summary

Dialectical Behavior Therapy (DBT; Linehan, 1993) effectively diminishes emotion dysregulation and self-harm behaviors in a number of disorders. However, to our knowledge, no studies have investigated the efficacy of DBT to treat emotional dysregulation associated with self-harm and suicidal behaviors in adults with ASD without intellectual disability. This randomized controlled study trial aims to assess the efficacy of a 5-month DBT intervention in adults with ASD without intellectual disability who present with self-harm and/or suicidal behaviors.

Interventions

Dialectical Behavior Therapy (DBT)

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years old * ASD diagnosis according to the DSM-5 * IQ ≥ 70 * Suicidal ideas, suicidal attempts and/or self-harm behaviors 6 months prior to the inclusion * Able to understand and consent to the research aims * Membership in a health insurance fund

Exclusion criteria

* complete hospitalization * ongoing CBT or DBT * past DBT * schizophrenia disorders * under guardianship

Design outcomes

Primary

MeasureTime frameDescription
Difficulties in Emotion Regulation Scale (DERS)baselineThe minimum value of the DERS scale is 0 and the maximum is 180. The higher the scores, the more severe the deregulation.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026